Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can someone please provide an update on the status of the criminal case against Pourhassan.
Matinas deserves congratulations for getting publication of the ENACT trial results in a per reviewed journal.
Unfortunately, the position taken by the FDA regarding a Phase 3 trial for MAT 2203 for invasive fungal infections has made to impractical for Matinas to conduct such a study.
In light of this setback, I think it would make sense for Matinas to go back to the original plan—a Phase 3 pivotal trial for CM.
Approval for this indication would validate MAT 2203 as a viable drug, and Matinas as a promising company, and could garner interest from potential partners.
While sales for CM would likely be modest, MAT 2203 could possibly be used off label for other indications that would help to validate the use of MAT 2203 for other IFI (along with the LPAD pathway).
Matinas sorely needs a “W,” and getting approval of MAT 2203 for some indication could be the win it needs to get positive recognition and possible funding.
LM
The SEC action against Pourhassan could be good news for the company in that it seeks disgorgement of the profits Porhassan made as a result of his alleged fraud.
That money could be invaluable to the company which is running on fumes, in large part, in my opinion, because of Pourhassan's alleged misconduct.
LM
HYFM's CEO, Bill Toler, recently purchased an additional 25,000 shares, and now owns over 1.6 million shares.
Toler, who has a history of turning around companies, such as Hostess Brands, has far better knowledge than the market as to the company's prospects, and has a substantial, and increasing, stake in Hydrofarm.
Although HYFM is not now cash flow positive, that is true of most companies in the cannabis space.
However, it is reasonable to assume, as has Toler, that cannabis sales will increase, and companies such as HYFM will again become cash flow positive, due to more marijuana being grown as a result of changing demographics and permissive legislation.
AVXL needs someone to speak on behalf of the company, and its drugs, in a clear, coherent, and straightforward manned. Missling lacks the ability to do this, and should be replaced, at least in this role.
I would be surprised if Anavex-273 does not do better than a 27% reduction in cognitive decline compared to placebo which was the result of the Lecanemab study. In that Anavex-273 does not appear to result in the serious adverse events experienced with Lenanemcab, any improvement in cognitive decline of 27% or more in Alzheimer's patients would likely result in a favorable reception from the FDA as well as the market.
In recessions, sin stocks tend to go way up. So if history is any guide, and we go into a recession, I expect people to smoke more pot, and the share price of HYFM to increase substantially from the current depressed levels.
There are three people to blame for this mess in my opinion.
One of the people to blame was terminated, one left long ago, and the other should be terminated in my opinion.
Each of these people made multi-millions by selling their stock while the leader was telling the shareholders everything was great.
This would seem to add to the issues being investigated by the SEC and DOJ with respect to CYDY's ousted president, Nader Pourhassan, given that he downplayed the HIV BLA issues when addressing the shareholders.
Following is a comment I posted today on Biontech's website:
I am writing to you as a shareholder of both Biontech (BNTX) and Matinas Biopharma (MTNB).
It has been almost six months since BNTX paid almost $4 million USD for the exclusive negotiating rights to license MTNB's liquid nano crystal (LNC) delivery system.
Although I understand BNTX has had its scientists working with MTNB even before this six month exclusivity period started, no agreement has as yet been reached with MTNB.
It appears obvious that a collaboration with MTNB for use of its LNC delivery platform would be in the best interests of BNTX, MTNB, and the world, as it would allow BNTX's mRNA drugs--that now have to be administered intravenously, and stored at extremely cold temperatures--to be delivered orally, and stored, for many months, at room temperature.
LNC delivery has the added benefit of having far fewer side effects than delivery of mRNA drugs and vaccines using LNP.
In addition, because MTNB owns the rights to use of LNC, and BNTX's patents on LNP are being challenged by Moderna, and others, licensing MTNB's LNC delivery platform, for use with existing and future mRNA drugs and vaccines, provides for legal certainty that does not exist with LNP.
As I am sure you know, the safety and effectiveness of MTNB's LNC delivery system has recently been validated in a clinical trial for the LNC version of amphotericin b for patients with cryptococcal meningitis (CM) where an astounding 90-95% of the patients are still alive after six weeks, with minimal side effects. In that CM is 100% fatal if left untreated, and the LNC version of amp b handily bested the standard of care with far fewer adverse events, while crossing the blood brain barrier, these results are highly promising for BNTX's mRNA drugs and vaccines.
For all of these reasons, it is puzzling that BNTX would not have already entered into a licensing agreement with MTNB for use of its LNC delivery system.
I am sure BNTX has its reasons for not having already entered into a licensing agreement with MTNB. However, given the importance of this collaboration--not only to not to BNTX and MTNB, but to the world--I would urge BNTX to finalize its agreement with MTNB before its one-year exclusivity period ends in April 2023, when MTNB will be at liberty to license its LNC platform to Moderna, Pfizer, or any other companies who are developing mRNA drugs.
Thank you,
XXXXXXXXXXX
Shareholder of BNTX and MTNB
FDA 501(k) clearance for 30 day use of the EVO sEEG system is huge news, and takes the shackles off of Zimmer Biomet to market this product.
The share price drop, in the face of this great news, is perplexing, but will likely be followed by a sharp rebound once this news is fully processed by the market.
It has been over six months since BNTX paid almost $4 million for the exclusive rights to do a deal with MNTB to use its lipid nano crystal delivery platform for BNTX's mRNA drugs.
If the parties had decided to terminate this agreement, one or both would have presumably issued a press release.
Rather, today, at the Think conference, JJ confirmed this deal was still alive, and he hoped to close it, along with an agreement for MAT 2203, by the end of 2022.
My guess is that BNTX and MTNB are working on a really big deal that takes time to construct, and that potential partners are reviewing the data on the ENACT trial, given the stellar results announced to date.
If I am reading the tea leaves correctly, this could be a very happy new year for MTNB and its shareholders.
The board needs to explain the claims made by Urvan who is not only a director, but the company's largest shareholder.
In addition, Urvan needs to host a call for interested shareholders to explain his position, and answer their questions.
Regardless of the results of the Anavex clinical trials, I believe some of its constant critics will claim the results are flawed.
In fact, my belief is that such negative articles, posts, and twits have likely already been prepared, and will be launched soon after the results of the Alzheimer's trial are announced.
I hope I am wrong, but if history is any guide, my guess is that I am right.
If BNTX and MTNB were to collaborate, the combination would be formidable. BNTX, with its MRNA technology, and MTNB, with its lipid nano crystal delivery system, would result in MRNA drugs being safer, oral, and transportable at room temperature.
I expect big things for MTNB's share price once it licenses use of its liquid nano crystal drug delivery system to BNTX. MTNB's LNC drug delivery system--which is far more effective and less toxic than the liquid nano particle system now used by BNTX and other vaccine makers--will enable BNTX to make its injectable vaccines oral, without the side effects normally associated with MRNA therapeutics delivered using LNPs.
According to MTNB, a licensing agreement with BNTX is expected within the next few months.
CI:
I hope the board tries to claw back some of that money.
LM
For those of you who place no blame on Pourhassan for the mess the company is now in, or for the losses we as shareholders are suffering, remember this:
While Pourhassan was telling shareholders the share price was going to triple digits, that the FDA refuse to file letter was the result of a minor packaging error that would be quickly corrected, and that the Covid-19 clinical trials were a great success, he sold his shares for a huge multi-million dollar profit, before the board finally terminated his employment.
I am holding about 150,000 shares I fear are about to become worthless.
So am I upset with Pourhassan?
You are darned right I am.
LM
Here are the questions I submitted to Investor Relations for tomorrow's call:
1. Has or will the company seek to claw back any of the shares issued to Nader Pourhassan?
2. Has or will the company seek to claw back any of the compensation paid to Nader Pourhassan?
3. Was Nader Pourhassan terminated for cause?
4. What is the reason the company terminated Nader Pourhassan without having another CEO ready, or even in mind at the time, to replace him?
5. How much cash does the company now have on hand?
6. How much money is currently owed to Fife or his company, and what are the terms for repaying this debt?
7. What is the company’s plan to obtain funding for future operations?
8. What is the status of the search for a new CEO?
9. What clinical trials are now ongoing, and what clinical trials had to be stopped due to a lack of funding?
10. What potential catalysts does the company have that may occur within the next six months?
Russia supplies 40% of the world's ammunition.
The US has banned Russian ammunition commencing in 2023.
With the developments in Ukraine, I would hope the Russian ammunition ban would be made effective immediately.
If so, that would leave a void that POWW could fill.
If CYDY hires a competent CEO, with good credibility, I think the FDA will bend over backwards to give Leronlimab fair consideration knowing that its issues with the company were likely due to the incompetence of the previous CEO.
My opinion, for what it's worth.
Even after he has been terminated, the ghost of Pourhassan continues to plague the company.
I only hope the company can survive the damage he has done.
I would appreciate any feedback on whether the company has issued an 8-K stating (1) if Pourhassan was terminated for cause, (2) if Pourhassan was given a compensation package upon leaving, or (3) if the company intends to try and claw back some of the shares that were issued to him.
Good news about the bond.
Next, the company needs to find a competent CEO, preferably one who has experience running a clinical state biopharmaceutical company.
The first order of business for the new CEO should be to raise financing.
The second order of business should be to terminate any board members who failed to protect the interests of the shareholders by not replacing the former CEO long before they did.
HYFM insiders have invested heavily in the stock, and have not sold any shares except to pay taxes. That, to me, is a very positive sign.
Someone please update this site to show current management, rather than Pourhassan and Mulholland.
Marijuana is the elephant in the room for all hydroponics companies such as GRWG and HYFM.
Although CEA is a promising industry, it is the hydroponic growing of marijuana that will fuel the future growth of these companies.
While there is a glut of marijuana in many markets, especially California, when this is burned off (pun intended), more marijuana will be grown, and much more hydroponics equipment and supplies will be needed to grow it hydroponically.
As a very large purveyor of hydroponics equipment and supplies, the sales of GRWG and Hydrofarm should increase dramatically in the coming quarters and years that make today's fire sale prices a bargain, in my opinion.
LM
Marijuana is the elephant in the room for all hydroponics companies such as HYFM.
Although CEA is a promising industry, it is the hydroponic growing of marijuana that will fuel HYFM's future growth.
While there is a glut of marijuana in many markets, especially California, when this is burned off (pun intended), more marijuana will be grown, and much more hydroponics equipment and supplies will be needed to grow it hydroponically.
As a very large purveyor of hydroponics equipment and supplies, Hydrofarm's sales should increase dramatically in the coming quarters and years that make today's share price a bargain at today's fire sale price, in my opinion.
LM
Excellent analysis RealFoo.
President Obama's campaign slogan, "Change," clearly applies to Cytodyn at this point in time.
In order to salvage the company, and get approval for a promising drug, Pourhassan needs to be replaced NOW.
This is the same Pourhassan who sold most of his stock (none of which he purchased) at much higher prices, netting him around $15 million, while telling shareholders the share price would go to triple digits.
This is the same Pourhassan who was roundly criticized by a Delaware judge, rebuked by the FDA, and is the subject of current investigations by the SEC and DOJ.
While the company is on financial life support, Pourhassan continues to receive a $10 million compensation package, which is higher than CEO's of many prominent and highly profitable companies.
If Pourhassan will not resign, and if he is not forced out by the SEC or DOJ, the shareholders need to band together and convene an emergency meeting in which Pourhassan is ousted, along with Kelly.
For $10 million a year, Cytodyn could replace Pourhassan with a seasoned biopharma CEO who has a track record of successfully turning around distressed companies.
My opinions, for what they are worth.
LM
The stock price should have gone way up on today's good news affirming guidance on revenues and construction of the munitions factory.
Eventually, the share price will catch up to the fundamentals.
Hydrofarm is way oversold, and I expect a strong recovery in the share price by the end of the year.
The CEO, Bill Toler, has invested millions of his own money in this company, and has a solid track record of increasing shareholder value.
With revenues and profits projected to recover later this year, the share price should follow.
For those of you who recently voted to retain Pourhassan, and the current board, and to affirm the executive compensation package, do you now believe, in hindsight, that this was a mistake?
If you still believe this was a prudent decision, I welcome your thoughts as to why you continue to think this was the right thing to do.
LM
Does today's communication from the FDA constitute a more accepting posture towards Leronlimab and Cytodyn by the FDA?
Could this revised position of the FDA have anything to do with Janet Woodcock's departure?
Scott's Miracle-Gro announced today that sales for its Hawthorne (hydroponics) unit are expected to grow by 8 to 12% in the second half of 2022.
This bodes well for HYFM.
Hope springs eternal, HG.
However, I harbor no allusions that Pourhassan will ever agree not to take any of the 200 million shares for himself.
Good idea C-20.
However, Pourhassan and Kelly will never go for it.
I doubt you will even get the courtesy of a response.
In my opinion, those two need to be voted out if Cytodyn has any chance of success.
I agree, HG.
However, there is no reason the company cannot assure shareholders that none of the 200 million shares will be awarded to current management.
I have been invested in Cytodyn for over 6 years, having participated in numerous Paulson raises, and continue to be heavily invested.
I continue to be invested b/c of LL, and in spite of Pourhassan who, in my opinion, has received far too much compensation already, and should now assure the SH he will take no more shares from the 200M shares if approved by the SH.
For those who are opposed to management assuring the SH they will take no more shares from the 200M if the SH approve them, please explain your rationale.
In that Pourhassan has publicly stated he reads message boards, such as this, let me repeat the offer previously made on this board :
Agree that management will not award any of the 200 million new shares to themselves, and I, and I expect many other shareholders, will vote to approve the issuance of these shares.
If this offer is not accepted, I think it would be fair to assume that management will again use shares approved by the shareholders to reward themselves.
LM